Beckman Coulter, Fujirebio Diagnostics, and Roche Diagnostics are established in the biomarker industry and produce FDA-approved standards (that are classified as antibody-defined tumor markers) for CA19-9, CEA, and CA125 (MUC16) clinical assays [11]. The gene discussed is MUC16; the disease is neoplasm.